• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study.

作者信息

Lolli Ginevra, Argnani Lisa, Broccoli Alessandro, Marangon Miriam, Pellegrini Cinzia, Morigi Alice, Casadei Beatrice, Nanni Laura, Stefoni Vittorio, Carella Matteo, Cavo Michele, Zinzani Pier L

机构信息

Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

出版信息

Br J Haematol. 2020 Apr;189(1):e6-e9. doi: 10.1111/bjh.16404. Epub 2020 Jan 13.

DOI:10.1111/bjh.16404
PMID:31944265
Abstract
摘要

相似文献

1
Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study.钇-伊布替膦酸在黏膜相关淋巴组织结外边缘区B细胞淋巴瘤（MALT淋巴瘤）患者中的应用——芝诺研究
Br J Haematol. 2020 Apr;189(1):e6-e9. doi: 10.1111/bjh.16404. Epub 2020 Jan 13.
2
Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.⁹⁰钇-替伊莫单抗治疗复发/难治性结外边缘区淋巴瘤的疗效。
Hematol Oncol. 2014 Mar;32(1):10-5. doi: 10.1002/hon.2078. Epub 2013 May 20.
3
90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.90Y-替伊莫单抗（Zevalin）治疗重度预处理的黏膜相关淋巴组织淋巴瘤患者。
Leuk Lymphoma. 2011 Jan;52(1):42-5. doi: 10.3109/10428194.2010.534519. Epub 2010 Dec 6.
4
Rituximab-PECC induction followed by Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.在不适合或经 ASCT 治疗失败的复发/难治性弥漫性大 B 细胞淋巴瘤患者中，采用利妥昔单抗-PECC 诱导联合 Y-替伊莫单抗替奥单抗巩固治疗：一项 II 期 HOVON 研究结果。
Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.
5
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.钇-90替伊莫单抗（泽瓦林）靶向放射免疫疗法用于早期结外惰性眼附属器淋巴瘤一线治疗的前瞻性试验。
Ann Oncol. 2009 Apr;20(4):709-14. doi: 10.1093/annonc/mdn692. Epub 2009 Jan 15.
6
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.氟达拉滨、米托蒽醌和利妥昔单抗联合治疗联合钇-90 替伊莫单抗替西他滨和维持性利妥昔单抗作为滤泡性或边缘区淋巴瘤患者一线治疗的安全性和有效性。
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.
7
Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.利妥昔单抗、环磷酰胺、长春新碱和泼尼松治疗黏膜相关淋巴组织胃边缘区B细胞淋巴瘤
Hematol Oncol. 2014 Sep;32(3):139-44. doi: 10.1002/hon.2105. Epub 2013 Oct 9.
8
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.钇-90替伊莫单抗（泽瓦林）治疗初治边缘区淋巴瘤患者的II期研究
Leuk Lymphoma. 2015 Jun;56(6):1750-5. doi: 10.3109/10428194.2014.975801. Epub 2014 Nov 20.
9
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.钇-90标记的替伊莫单抗放射免疫疗法与利妥昔单抗免疫疗法治疗复发或难治性低度、滤泡性或转化型B细胞非霍奇金淋巴瘤患者的随机对照试验
J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076.
10
Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.边缘区B细胞淋巴瘤：淋巴结型与黏膜相关淋巴组织型的临床比较。非霍奇金淋巴瘤分类项目。
J Clin Oncol. 1999 Aug;17(8):2486-92. doi: 10.1200/JCO.1999.17.8.2486.

引用本文的文献

1
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.抗 CD20 放射性免疫疗法在淋巴瘤临床应用的系统评价
Oncologist. 2024 Apr 4;29(4):278-288. doi: 10.1093/oncolo/oyad333.
2
Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.提高结外边缘区淋巴瘤的预后预测和实现个体化治疗。
Expert Rev Hematol. 2023 May;16(5):333-348. doi: 10.1080/17474086.2023.2206557. Epub 2023 Apr 28.
3
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.滤泡性和边缘区淋巴瘤的无化疗管理
Cancer Manag Res. 2021 May 14;13:3935-3952. doi: 10.2147/CMAR.S267258. eCollection 2021.
4
How do we sequence therapy for marginal zone lymphomas?我们该如何为边缘区淋巴瘤进行序贯治疗？
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):295-305. doi: 10.1182/hematology.2020000157.